Selectivity of angiotensin II antisera

Area of Science:

• Immunology
• Biochemistry
• Endocrinology

Background:

• Immunoassays for angiotensin II often suffer from cross-reactivity with its metabolic products.
• This cross-reactivity complicates accurate measurement of angiotensin II levels.

Purpose of the Study:

• To generate highly selective antisera for angiotensin II.
• To develop antibodies that specifically recognize the amino terminus of angiotensin II, minimizing reactions with degradation products.

Main Methods:

• Conjugation of angiotensin II or its derivatives to carrier proteins (rabbit serum albumin, thyroglobulin).
• Immunization strategies included using N-acetylated angiotensin II-amide coupled via its carboxy terminus and angiotensin-(1-7)-heptapeptide coupled randomly.
• Characterization of antisera specificity against various angiotensin II forms and metabolic products.

Main Results:

• Immunization with N-acetylated angiotensin II-amide yielded antisera that recognized the N-terminally modified peptide but not the native human hormone.
• Immunization with angiotensin-(1-7)-heptapeptide also produced selective antisera by removing the C-terminal epitope.
• Other conjugation methods, like C-terminal coupling without N-acetylation or diazo bonding to His6, did not achieve amino-terminal selectivity.

Conclusions:

• N-acetylation of angiotensin II-amide immunogens protects against aminopeptidases, preserving the N-terminal structure for antibody recognition.
• Using truncated peptides like angiotensin-(1-7) effectively removes immunodominant C-terminal epitopes, thereby directing antibody response to the N-terminus.
• These methods offer a viable strategy for developing specific angiotensin II immunoassays.